Literature DB >> 15539386

Analysis of insulin-like growth factors and insulin-like growth factor I receptor expression in renal cell carcinoma.

Luigi Schips1, Richard Zigeuner, Manfred Ratschek, Peter Rehak, Josef Rüschoff, Cord Langner.   

Abstract

The expression of insulin-like growth factors I (IGF-I) and II (IGF-II) and insulin-like growth factor-I receptor (IGF-IR) was studied in 137 clear cell, 23 chromophobe, and 20 papillary renal cell carcinomas (RCCs) using a tissue microarray technique. IGF-I immunoreactivity was detected in 110 (82.1%) of 134 clear cell, 8 (36%) of 22 chromophobe, and 3 (15%) of 20 papillary RCCs (P < .001). IGF-IR immunoreactivity was detected in 39 (29.5%) of 132 clear cell, 9 (41%) of 22 chromophobe, and 19 (95%) of 20 papillary RCCs (P < .001). In contrast, all tumors lacked IGF-II expression. Expression of IGF-I and IGF-IR was not related to tumor stage, grade, or prognosis. The IGF system is expressed differentially among different tumor types. The expression of IGF-I together with its receptor, IGF-IR, provides evidence for the existence of an autocrine-paracrine loop of tumor cell stimulation in RCC and makes this type of cancer a candidate for therapeutic strategies aimed to interfere with the IGF pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539386     DOI: 10.1309/G7PY-0RE7-T86H-HQYV

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  14 in total

Review 1.  Antineoplastic effects of mammalian target of rapamycine inhibitors.

Authors:  Maurizio Salvadori
Journal:  World J Transplant       Date:  2012-10-24

2.  Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours.

Authors:  P Kornprat; P Rehak; J Rüschoff; C Langner
Journal:  J Clin Pathol       Date:  2006-02       Impact factor: 3.411

3.  Menstrual cycle characteristics and incident cancer: a prospective cohort study.

Authors:  Siwen Wang; Yi-Xin Wang; Helena Sandoval-Insausti; Leslie V Farland; Jan L Shifren; Dan Zhang; JoAnn E Manson; Brenda M Birmann; Walter C Willett; Edward L Giovannucci; Stacey A Missmer; Jorge E Chavarro
Journal:  Hum Reprod       Date:  2022-01-28       Impact factor: 6.918

Review 4.  Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.

Authors:  Ruirong Yuan; Andrea Kay; William J Berg; David Lebwohl
Journal:  J Hematol Oncol       Date:  2009-10-27       Impact factor: 17.388

Review 5.  Context-dependent regulation of receptor tyrosine kinases: Insights from systems biology approaches.

Authors:  Inez Lam; Christina M Pickering; Feilim Mac Gabhann
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2018-09-26

6.  MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells.

Authors:  Falguni Das; Nirmalya Dey; Amit Bera; Balakuntalam S Kasinath; Nandini Ghosh-Choudhury; Goutam Ghosh Choudhury
Journal:  J Biol Chem       Date:  2016-05-13       Impact factor: 5.157

7.  External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma.

Authors:  Nathan E Hoffmann; Yuri Sheinin; Christine M Lohse; Alexander S Parker; Bradley C Leibovich; Zhong Jiang; Eugene D Kwon
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

8.  Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro.

Authors:  Thomas M Cardillo; Preeti Trisal; Roberto Arrojo; David M Goldenberg; Chien-Hsing Chang
Journal:  BMC Cancer       Date:  2013-04-01       Impact factor: 4.430

9.  Insulin-like growth factors and risk of kidney cancer in men.

Authors:  J M Major; M N Pollak; K Snyder; J Virtamo; D Albanes
Journal:  Br J Cancer       Date:  2010-06-01       Impact factor: 7.640

10.  Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer.

Authors:  Y-F Huang; M-R Shen; K-F Hsu; Y-M Cheng; C-Y Chou
Journal:  Br J Cancer       Date:  2008-09-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.